Abstract:Glioblastoma is the most aggressive primary brain tumour, with a median survival of just fifteen months with treatment. Standard-of-care (SOC) for glioblastoma consists of resection followed by radio- and chemotherapy. Clinical trials involving PD-1 inhibition with nivolumab in combination with SOC failed to increase overall survival. A quantitative understanding of the interactions between the tumour and its immune environment driving treatment outcomes is currently lacking. As such, we developed a mathematical model of tumour growth that considers cytotoxic CD8+ T cells, pro- and antitumoral tumour-associated macrophages and microglia (TAMs), SOC, and nivolumab. Our results show that PD-1 inhibition fails due to a lack of CD8+ T cell recruitment during treatment explained by TAM-driven immunosuppressive mechanisms. Using our model, we studied five TAM-targeting strategies currently under investigation for solid tumours. Our model predicts that while reducing TAM numbers does not improve prognosis, altering their functions to counter their protumoral properties has the potential to considerably reduce post-treatment tumour burden. In particular, restoring antitumoral TAM phagocytic activity through anti-CD47 treatment in combination with SOC was predicted to nearly eradicate the tumour. By studying time-varying efficacy with the same half-life as the anti-CD47 antibody Hu5F9-G4, our model predicts that repeated dosing of anti-CD47 provides sustained control of tumour growth. Thus, we propose that targeting TAMs by enhancing their antitumoral properties is a highly promising avenue to treat glioblastoma and warrants future clinical development. Together, our results provide proof-of-concept that mechanistic mathematical modelling can uncover the mechanisms driving treatment outcomes and explore the potential of novel treatment strategies for hard-to-treat tumours like glioblastoma.

Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape

Targeting immune checkpoints on tumor-associated macrophages in tumor immunotherapy.

Tumor-associated microglia and macrophages in glioblastoma: From basic insights to therapeutic opportunities

Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities

Tumor Associated Macrophages, as the Dominant Immune Cells, Are an Indispensable Target for Immunologically Cold Tumor—Glioma Therapy?

The two-sided battlefield of tumour-associated macrophages in glioblastoma: unravelling their therapeutic potential

Targeting tumor-associated macrophages to synergize tumor immunotherapy

Tumor-associated macrophage-related strategies for glioma immunotherapy

Targeting Tumor-Associated Macrophages As an Antitumor Strategy.

Single-Cell Transcriptomics of Glioblastoma Reveals a Unique Tumor Microenvironment and Potential Immunotherapeutic Target Against Tumor-Associated Macrophage

Targeting tumor-associated macrophages for cancer treatment

Microglia and macrophages in glioblastoma: landscapes and treatment directions

Identification of hypoxic macrophages in glioblastoma: Unveiling therapeutic insights from tumour microenvironment analysis

Immunotherapies Targeting Tumor-Associated Macrophages (TAMs) in Cancer

Tumor-associated macrophages: A promising target for a cancer immunotherapeutic strategy

Targeting Tumor-Associated Macrophages in Cancer Immunotherapy

Emerging Role of Tumor-associated Macrophages As Therapeutic Targets in Glioblastoma Multiforme

Harnessing Tumor-Associated Macrophages As Aids for Cancer Immunotherapy

Progress in Tumor‐Associated Macrophages: from Bench to Bedside

Virtual clinical trial reveals significant clinical potential of targeting tumour-associated macrophages and microglia to treat glioblastoma

Crosstalk Between Tumor-Associated Microglia/Macrophages and CD8-Positive T Cells Plays a Key Role in Glioblastoma.